Interagency Patent Coordination and Improvement Act of 2025

The Interagency Patent Coordination and Improvement Act of 2025 would establish a new task force to facilitate better communication and information sharing between the U.S. Patent and Trademark Office (USPTO) and the Food and Drug Administration (FDA). The task force would focus specifically on patents related to human drugs and biological products, helping these two agencies understand each other's processes and share information about patent approvals, drug approvals, and new technologies.

Under this bill, the USPTO would be able to request information from the FDA about certain patent applications to help patent examiners make better decisions, while the FDA would provide that information. Additionally, the USPTO would assist the FDA with its administrative duty of maintaining a list of patents. If enacted, this coordination could potentially streamline the patent review process for pharmaceutical companies and help ensure that patent examiners have relevant information about drug development timelines and FDA approvals.